A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...

A new research perspective titled "Targeting the multifaceted BRAF in cancer: New directions" has been published in Oncotarget. In cancer patients, BRAF-targeting precision therapeutics are effective ...

Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events ...

A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions." In cancer patients, BRAF-targeting precision ...

The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...